Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Eye Company Formed

April 2, 2007 | A version of this story appeared in Volume 85, Issue 14

Acuity Pharmaceuticals and Froptix have agreed to merge with eXegenics, a publicly traded company with no current active operations, to form a new firm, Opko, listed on the American Stock Exchange. Acuity and Froptix both have drug discovery efforts in eye disease. Acuity has two drugs in development: bevasiranib, in Phase II trials for wet macular degeneration, and a product in Phase I trials for conjunctivitis. Froptix has a range of small molecules in preclinical studies. Opko has received a $12 million credit line from the Frost Group to help fund a Phase III trial of bevasiranib.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.